379 studies found for:    Open Studies | "Carcinoma, Hepatocellular"
Show Display Options
Rank Status Study
21 Recruiting Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Interventions: Drug: Doxorubicin;   Drug: Best Supportive Care
22 Recruiting Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
Condition: Carcinoma, Hepatocellular
Intervention: Drug: Refametinib (BAY86-9766)
23 Recruiting Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
Condition: Carcinoma, Hepatocellular
Interventions: Drug: Refametinib (BAY86-9766);   Drug: Sorafenib (BAY43-9006)
24 Recruiting Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
Conditions: Adult Primary Hepatocellular Carcinoma;   Adult Primary Undifferentiated Hepatocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Childhood Hepatocellular Carcinoma;   Localized Unresectable Adult Primary Liver Cancer;   Recurrent Adult Primary Liver Cancer;   Recurrent Childhood Liver Cancer;   Stage C Adult Primary Liver Cancer (BCLC);   Stage D Adult Primary Liver Cancer (BCLC);   Stage III Childhood Liver Cancer;   Stage IV Childhood Liver Cancer
Interventions: Drug: sorafenib tosylate;   Other: laboratory biomarker analysis
25 Recruiting A Study of LY2157299 in Participants With Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Interventions: Drug: LY2157299;   Drug: Sorafenib
26 Recruiting Circulating Tumor Cells for Hepatocellular Carcinoma
Conditions: Carcinoma, Hepatocellular;   Neoplasm Circulating Cells
Intervention:
27 Recruiting Dose Escalation Study for Primary Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Intervention: Radiation: Stereotactic Body Radiation
28 Recruiting A Dose-escalation Study of Lipotecan® Plus Radiotherapy in Locally Advanced Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Intervention: Drug: Lipotecan® (TLC388)
29 Not yet recruiting Radiofrequency Ablation in Treating Patients With Liver Cancer (Hepatocellular Carcinoma)
Condition: Carcinoma, Hepatocellular
Interventions: Procedure: radiofrequency ablation;   Procedure: laparoscopy
30 Recruiting Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Interventions: Drug: Regorafenib (BAY73-4506);   Drug: Placebo
31 Recruiting Comparison Study of Sorafenib and 5-fluorouracil/Mitomycin for Metastatic Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Interventions: Drug: 5-FU;   Drug: Mitomycin;   Drug: sorafenib
32 Recruiting Stereotactic Body Radiotherapy for Hepatocellular Carcinoma, and Intrahepatic Cholangiocarcinoma
Conditions: Carcinoma, Hepatocellular;   Intrahepatic Cholangiocarcinoma
Intervention: Radiation: Stereotactic radiation
33 Recruiting Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Interventions: Drug: Nintedanib high dose;   Drug: Nintedanib low dose;   Drug: Nintedanib medium dose
34 Not yet recruiting Safety and Efficacy of Arsenic Trioxide Contained in TACE in the Treatment of HCC
Condition: Carcinoma, Hepatocellular
Interventions: Drug: TACE containing As2O3;   Drug: TACE containing placebo
35 Recruiting Humanitarian Device Exemption (HDE) Treatment Protocol
Conditions: Carcinoma, Hepatocellular;   Liver Cancer
Intervention: Device: TheraSphere Treatment
36 Unknown  The Role of Low Molecular Weight Heparins (LMWH) Combined With Transarterial Chemoembolization (TACE) in Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma
Interventions: Drug: LMWH;   Procedure: TACE
37 Recruiting TheraSphere® for Treatment of Unresectable Hepatocellular Carcinoma
Conditions: Hepatocellular Carcinoma;   Liver Cancer;   Liver Neoplasm;   Primary Liver Cancer
Intervention: Device: TheraSphere
38 Recruiting Study of Axitinib in Patients With Unresectable Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma
Intervention: Drug: Axitinib (AG-013736)
39 Unknown  188RE-SSS Lipiodol to Treat HepatoCellular Carcinomas
Condition: Hepatocellular Carcinomas
Intervention: Drug: 188Re-SSS Lipiodol
40 Not yet recruiting TH-302 Plus Doxorubicin Delivered by Trans-Arterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma
Interventions: Drug: Phase I Dose level -1;   Drug: Phase I dose level 1;   Drug: Phase I Dose level 2;   Drug: Phase I Dose level 3

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years